AO-176 

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma^[1][2][3][4].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

CD47

AO-176 shows EC₅₀ values of 130 ng/mL (OV90), 390 ng/mL (HCC827), 649 ng/mL (SNU-1), 250 ng/mL (OV10-315), 2700 ng/mL (MDA-MB-231), 390 ng/mL (Jurkat) and 1910 ng/mL (Raji)^[1].

AO-176 (10 μg/mL, 24 h) induces death of Jurkat and OV90 cells^[1].

AO-176 (0.017-1000 μg/mL) binds negligibly to RBCs and does not cause agglutination of washed human RBCs^[1][3].

AO-176 (10-30 μg/mL, 24 h) has no killing effect on normal cell and the activated T cells^[1].

AO-176 (0.001-100 μg/mL, 90 min) directly inhibits the binding of SIRPα to CD47 on Jurkat cells with an IC50 of 0.78 to 0.87 μg/mL^[1].

AO-176 (0.01-10 μg/mL, 2 h) promotes the phagocytosis of both Jurkat, Raji, OV90, Detroit 562, and FaDu cells in a concentration-dependent manner^[1][2][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AO-176 (1-25 mg/kg, i.v., weekly for 4 weeks) significantly suppresses the tumor growth in Raji lymphoma xenograft mice models^[1].

AO-176 (10-25 mg/kg, i.p., weekly or 5 times/weeks for 5-6 weeks) significantly suppresses the tumor growth in MDA-MB-23, SNU-1 and OV90 xenograft mice models^[1].

AO-176 (3-25 mg/kg) exerts anti-tumor activity in RPMI-8226 and NCI-H929 xenografted mice models^[3][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

961  [NCBI]

Q08722

CD47

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

2691109-74-5

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.  [Content Brief]

  [2]. Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721.  [Content Brief]

  [3]. William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1): 3–4

  [4]. John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1): 1844.